Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
1 clinical trials · Condition
◉ Watch Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
| Record | Firm | Date |
|---|---|---|
| Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (NCT04215016) | Fujian Medical University | 2019-12-01 |
Track Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive automatically
Every clearance here is in the API, with alerts when new ones post.